California Heart Center Foundation

“Cedars-sinai medical center is the sole corporate member of california heart center foundation.”

“Cedars-sinai medical center, as the sole corporate member, elects board of directors to california heart center foundation.”

“Reserved rights of cedars-sinai medical center, the sole corporate member of the organization. The following actions must be approved or acted upon by cedars-sinai medical center before becoming effective: (a) any sale or other disposition of all or a substantial portion of the assets of the organization; (b) any merger or affiliation of the organization with any person or entity other than the member; (c) any amendment to the articles of incorporation or bylaws of the organization; (d) any act or omission which creates any material risk to the member's tax-exempt status, or creates any material risk of a violation of any state or federal laws; (e) dissolution of the organization or the filing of any bankruptcy petition; (f) creation of any new corporation, partnership or association; (g) acquisition of or the investment in a new operating business; (h) entering into any partnerships or joint ventures; (i) adoption of or changes to operating or capital budgets; (j) adoption of this corporation's policies and procedures; (k) execution and delivery of any new affiliation agreements and other relationships with the ucla school of medicine and other institutions of medical learning; (l) unbudgeted capital expenditures over $100,000; (m) loans, borrowings or guarantees in excess of $100,000, unless approved in the budget; (n) any security interests or mortgages on the property of organization; (o) operating or capital leases where the term is over five years or the total obligation under the lease exceeds $100,000, unless approved in the budget; (p) termination or selection of the auditors of the organization; (q) appointment or removal of any member of the board (other than ex-officio directors); (r) appointment of removal of any officers; (s) execution and delivery of any professional service agreements; (t) relocation of principal office; and (u) fixing the number of directors of the organization.”

“The organization's form 990 undergoes an intense and highly comprehensive review process. The review involves various management personnel and a big four accounting firm.”

“Conflict of interest policy annual statements: each director, officer, member of a committee with board-delegated powers and any other interested person as determined by the board or committee shall at least annually sign a copy of the "statement pertaining to conflict of interest." if a director, officer, or committee member, or designated interested person becomes aware that a potential or apparent conflict may exist which is not disclosed on such a statement, it shall be the responsibility of the interested person to disclose the potential conflict to the president and to the board or appropriate committee and as set forth above, prior to any board or committee discussions or action with respect to the relevant transaction or arrangement, and, if relevant, to leave the meeting during the discussion and vote on the transaction or arrangement. Determining whether a conflict of interest exists: if consideration of the transaction or arrangement at issue is a matter within the scope of authority of the board of directors or a committee, after disclosure of the financial interest and after any discussion with the interested person, the relevant california heart center foundation ("chcf") officer or administrator shall determine whether a conflict of interest exists. If it is determined that a conflict of interest exists and, notwithstanding the conflict, the chcf officer or administrator determines that it continues to be in the best interests of chcf to proceed with the transaction or arrangement at issue, the chcf officer or administrator shall refer the transaction or arrangement to the board or the appropriate board-designated committee for evaluation. Alternatively if consideration of the transaction or arrangement at issue is a matter within the scope of the authority of the board of directors or a committee, the interested person shall leave the board or committee meeting while the determination of the existence of a conflict of interest is discussed and voted upon. The remaining board or committee members shall decide, by majority vote, if a conflict of interest exists. Procedures for addressing the conflict of interest: a. An interested person may make a presentation to the board or committee regarding the transaction or arrangement. After such presentation the interested person must leave the meeting during the discussion of, and the vote on the transaction or arrangement. B. The chair of the board or committee shall, if deemed appropriate by the board or committee, appoint a disinterested person or committee to investigate alternatives to the proposed transaction or arrangement. C. After exercising due diligence, the board or committee shall determine whether chcf can obtain a more advantageous transaction or arrangement with reasonable efforts from a person or entity that would not give rise to a conflict of interest. D. If a more advantageous transaction or arrangement is not reasonably attainable under circumstances that would not give rise to a conflict of interest, the board or committee shall determine by a majority vote of the disinterested directors whether the transaction or arrangement is in chcf' best interest and for its own benefit and whether the transaction is fair and reasonable to chcf and shall make its decision as to whether to enter into the transaction or arrangement in conformity with such determination. Violations of the conflicts policy: a. If the board or committee has reasonable cause to believe that a member of the board or committee or an officer or other interested person has failed to disclose an actual or possible conflict of interest, it shall inform the member or officer or interested person of the basis for such belief and afford such person an opportunity to explain the alleged failure to disclose. B. If, after hearing the response of such person and making such further investigation as may be warranted in the circumstances, the board or committee determines that such person has in f”

“The executive personnel committee (the committee) of the tax-exempt parent of the organization, cedars-sinai medical center, is a standing committee of the board of directors. The committee addresses compensation and benefits regarding the organization's officers and board members who are also executive employees and contractually engaged faculty of the medical center, and is authorized by the board of directors to act with respect to such issues. The committee evaluates the performance and approves the compensation and benefits for the organization's officers and board members who are also executive employees and contractually engaged faculty of the medical center. Each year, the committee follows a process that ensures that the compensation and benefits is reasonable and in compliance with applicable laws and regulations. The medical center's svp of hr provides staff support to the committee. The committee may engage an independent compensation and benefits consultant, and any other advisors it deems necessary. The committee may also engage independent counsel. The medical center will provide for appropriate funding for payment of costs to any such persons retained by the committee. Annually, at the committee's direction, the independent compensation consultant shall prepare such reports as the committee reasonably deems necessary. At a minimum, such reports will include market survey data from a peer group designated by the committee, which shall be considered by the committee prior to making decisions.”

“The organization's conflict of interest policy and governing documents are not available to the public and its tax-exempt parent's audited consolidated financial statements are attached to the parent's form 990.”

“(continued) amyloidosis; phase 3 global, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of ion-682884 in patients with transthyretin-mediated amyloid cardiomyopathy (attr cm); patel amyloidosis; apollo-b: a study to evaluate patisiran in patients with transthyretin amyloidosis with cardiomyopathy (attr amyloidosis with cardiomyopathy); patel amyloidosis; eidos -ag310-301 (a phase 3, randomized, double-blind, placebo-controlled study of the efficacy and safety of ag10 in subjects with symptomatic transthyretin amyloid cardiomyopathy (attribute-cm trial)); patel amyloidosis; cardiac amyloidosis registry study (multi-center); patel amyloidosis; amyloidosis survey; patel heart failure; a double-blind, randomized, sham-procedure-controlled, parallel-group efficacy and safety study of allogeneic mesenchymal precursor cells (rexlemestrocel-l) in patients with chronic heart failure due to left ventricular systolic dysfunction of either ischemic or nonischemic etiology; chang heart failure; bariatric surgery and heart failure; hamilton heart failure; reducing lung congestion symptoms using the v-wave shunt in heart failure (relieve hf); hamilton heart failure; risk factors and outcomes in advanced heart disease; kobashigawa heart failure; dcm precision medicine study; kransdorf heart failure; dilated cardiomyopathy precision medicine study - cardiac mri substudy; kransdorf heart transplant; ocs heart perfusion post-approval registry ocs heart perfusion post- approval registry protocol; esmailian heart transplant; dcd-iit evaluating the safety of utilizing donor hearts from donation after circulatory death (dcd) donors compared to donor hearts from donation after brain death (dbd) donors: a single center pilot study; esmailian heart transplant; randomized trial to compare the sherpapak device vs cold storage of donor hearts in transplantation: a pilot study; esmailian heart transplant; the frequency and significance of blood type a1 donors to non-a1 subgroup recipients in heart transplantation; kittleson heart transplant; atg (a pilot randomized study to assess the effect and safety profile of thymoglobulin in primary cardiac transplant recipients: a 12-month, single center, randomized, open-label study of efficacy comparing immediate treatment with and without thymoglobulin 1.5 mg/kg/d for 5 consecutive days in heart transplant recipients); kobashigawa heart transplant; shore (surveillance heartcare outcomes registry); kobashigawa heart transplant; computer assisted cardiac histologic evaluation; kobashigawa heart transplant; targeting inflammation and alloimmunity in heart transplant recipients with tocilizumab; kobashigawa and patel heart transplant; infiltrating b cells in cardiac allograft vasculopathy; kransdorf heart transplant; immunologic risk study; kransdorf heart transplant; development of non-invasive cell-free dna to supplant invasive biopsy in heart transplantation-define-ht; kransdorf pulmonary hypertension; riociguat users registry - the roar registry; hage pulmonary hypertension; rin-ph-304: placebo-controlled, double-blind study to evaluate the safety and efficacy of inhaled treprostinil in patients with pulmonary hypertension due to chronic obstructive pulmonary disease (ph-copd); hage pulmonary hypertension; an observational study to characterize patient global impression questions for activity-induced symptoms in patients with pulmonary arterial hypertension; hage heart transplant; artoria study: an observational study regarding the outcome of adult patients with congenital heart disease (achd) or inherited cardiomyopathies undergoing heart or heart/lung transplantation; kobashigawa amyloidosis; alynam - aln-ttr02-014 expanded access protocol to provide patisiran to patients with transthyretin-mediated amyloidosis (attr amyloidosis) with cardiomyopathy; patel heart failure; novonordisk nn6019-4940: efficacy and safety of nnc6019-0001 at two dose levels in participants with tr”

“The organization was included in a consolidated, independent audited financial statements for the fiscal years ended 6/30/24 and 6/30/25 due to the fact that the tax year of its tax-exempt parent organization, cedars-sinai medical center, ends on 6/30. There are no audited financial statements for the year ended 12/31/24.”